Core Insights - SandboxAQ and MapLight Therapeutics have entered a strategic collaboration to develop therapies targeting a novel G protein-coupled receptor (GPCR) for central nervous system (CNS) disorders [1][2] Financial Terms - SandboxAQ received an upfront payment and is eligible for additional milestone payments totaling up to $200 million, which includes preclinical, development, regulatory, and commercial milestones [2] Research Collaboration - The collaboration will involve joint preclinical research activities, with MapLight holding exclusive rights for clinical development and commercialization of the compounds [2] - SandboxAQ will utilize large-scale AI models and high-fidelity molecular simulations to explore receptor structure-functional activity and optimize drug properties [3][4] Technological Advancements - The AQBioSim platform from SandboxAQ allows for precise simulation and prediction of molecular interactions with GPCRs, enhancing the exploration of chemical space and accelerating drug candidate optimization [4] Company Backgrounds - SandboxAQ is a B2B company focused on AI and quantum techniques, emerging from Alphabet Inc. and backed by leading investors [5] - MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing CNS disorders through circuit-specific pharmacotherapies [6]